Hematologic Malignancies: Myeloproliferative Disorders - part 1 ppsx

... Hospital Bethesda, MD 20892 Du Cane Road USA London W12 0NN UK ISBN -1 0 3-5 4 0-3 450 5 -1 Springer Berlin Heidelberg New York ISBN -1 3 97 8-3 -5 4 0-3 450 5-3 Springer Berlin Heidelberg New York Library of ... 543 210 –Printedonacid-free paper Contents 1. 1 Introduction 1 1.2 The 19 th Century 2 1. 2 .1 Clinical Aspects and Biology 2 1. 2.2 Therapy 4 1. 3 First Half of...

Ngày tải lên: 10/08/2014, 16:22

... J, Borzilleri RM (2004) Discovery of N-(2-chloro-6-methyl- phenyl )- 2-( 6-( 4-( 2-hydroxyethyl)-piperazin -1 - yl )-2 -methylpyrimidin-4 yla- mino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor ... Genes 2 21 13.2.2 .1 BCR-PDGFRA 2 21 13.2.2.2 FIP1L1-PDGFRA 222 13 .2.3 PDGFRB Fusion Genes 222 13 .2.3 .1 Multiple PDGFRB Partner Genes 222 13 .2.3.2 Clini...

Ngày tải lên: 10/08/2014, 16:22

... Features 264 15 .6 Prognosis 264 15 .7 Management 266 15 .7 .1 Medical Therapy 266 15 .7 .1. 1 Cytotoxic Therapy 266 15 .7 .1. 2 Androgens 266 15 .7 .1. 3 Erythropoietin 266 15 .7 .1. 4 Interferon 266 15 .7 .1. 5 Thalidomide ... 80 :18 4 18 8 Wang JC, Chen C, Lou LH, Mora M (19 97) Blood thrombopoietin, IL-6 and IL -1 1 levels in patients with agnogenic myeloid metaplasia. Leukemia...

Ngày tải lên: 10/08/2014, 16:22

... chromo- some regions must be particularly susceptible to break- age. These include: 1p36, 1q12–32, 3q 21, 3q26, 7p15, 11 q23, 12 p13, 12 q24, 13 q14, 14 q32, 17 p 11 13 , 17 q10 11 , 21q22, and 22q10 (Johansson et ... 23.0 10 0–249 14 5 36.2 250–350 69 17 .2 > 350 76 19 .0 Hb (g/dl) n % < 7.5 38 11 .0 7.6–9.4 81 23.5 9.5 11 .4 95 27.6 ³ 11 .5 13 0 37.8 Platelets (´ 10 9...

Ngày tải lên: 10/08/2014, 16:22

... 65 2 60 72 20 26 1 569 18 60 70 23 23 2 8 81 28 47 62 31 32 3 867 28 37 48 46 31 4 485 15 35 40 51 28 5 214 719 18 714 1 6 57 2 16 22 73 32 7 4––––– 5-year probability of leukemia-free survival (LFS), ... years CP1 22% >CP1 64% CP1 70% > CP1 56% (Das et al. 2003) 17 Fd/Bu/ATG (11 ) FD/Bu/TBI 16 CP1 1AP 17 Sib 35 5 molecular remission 30 months 8 /17 5 /17 6 /17 (Bornhauser...

Ngày tải lên: 10/08/2014, 16:22

... 18 9 11 .4.3 Donor Lymphoc yte Infusion 19 0 11 .5 Investigational Immune Therapies 19 1 11 .5 .1 Peptide Vaccines 19 1 11 .5 .1. 1 BCR-ABL 19 1 11 .5 .1. 2 Pr-3 and Pr -1 Vaccination . . . 19 4 11 .5 .1. 3 WT -1 194 11 .5.2 ... 18 7 11 .3 .1 T-Cells 18 7 11 .3.2 Natural Killer-Cells 18 8 11 .3.3 Antibodies 18 8 11 .4 Established Immune Therapies 18 9 11 .4 .1 Inte...

Ngày tải lên: 10/08/2014, 16:22

... PH, Ratcliffe PJ (19 98) Selection and analysis of a mutant cell line defective in the hypoxia-inducible factor -1 alpha-subunit (HIF- 1alpha). Characterization of hif-1alpha-dependent and -indepen- dent ... on the response. Blood 98 :10 19 10 27 a References 293 19 66; Clegg et al. 19 66; Harano et al. 19 83, 19 96; Moo- Penn et al. 19 87; Wajcman et al. 19 94; Williamson et al. 19 9...

Ngày tải lên: 10/08/2014, 16:22

... 22 81 19 43 37 (3·2) Fenaux et al. (19 90) 14 7 11 50 36 18 83 17 34 18 (4) Cortelazzo et al. (19 90) 10 0 11 35 34 11 91 9 30 9 (3) Colombi et al. (19 91) 10 3 12 00 73 23· 3 87 ·5 12 · 5 33 3 · 6 (1 ... 19 6 graft-versus-host disease (GvHD) 9, 12 0, 12 6, 18 7, 18 9, 19 7 graft-versus-leukemia (GvL) effect 12 1, 12 7, 17 1, 212 graft-versus-myelofibrosis (GvMy) ef-...

Ngày tải lên: 10/08/2014, 16:22

... given clone of antibody-producing cells. Idiotypes are formed by the unique structure of the antigen-binding portion of the molecule. Chapter 10 6. Plasma Cell Disorders (Part 1) Harrison's ... (Part 1) Harrison's Internal Medicine > Chapter 10 6. Plasma Cell Disorders Plasma Cell Disorders: Introduction The plasma cell disorders are monoclonal neoplasm...

Ngày tải lên: 07/07/2014, 04:20

... y0 w0 h1" alt=""

Ngày tải lên: 08/08/2014, 13:21